Table 2.
Group 2 patients’ characteristics.
| Patient ID. | N. of Eribulin Cycles | ECOG PS at PD | Indolent Disease at PD | Symptoms at PD | CB | OS (mos) | N. of Previous ET + CT before Eribulin | Treatment at PD | Response to Treatment at PD |
|---|---|---|---|---|---|---|---|---|---|
| 2 | 4 | Stable | No | No | Yes | 23.4 | 2 + 2 | NPLD | SD |
| 18 | 4 | Stable | No | No | Yes | 21.3 | 2 + 2 | Nab-P | PD |
| 22 | 4 | Stable | No | No | Yes | 11.5 | 3 + 2 | mCAPE | PD |
| 19 | 4 | Stable | No | No | Yes | 12.5 | 2 + 2 | mVNR + CAPE | PD |
| 8 | 4 | Stable | No | No | Yes | 14.8 | 2 + 2 | Nab-P | SD |
| 24 | 4 | Stable | No | No | Yes | 18.1 | 1 + 1 | EVE-EXE | PD |
| 27 | 4 | Stable | No | No | Yes | 11.0 | 2 + 1 | Palbo + Letro | PD |
| 34 | 4 | Stable | No | No | Yes | 20.4 | 0 + 2 | CAPE | SD |
| 43 | 4 | Stable | No | No | Yes | 13.4 | 3 + 1 | PLD | SD |
PD, progressive disease; CB, clinical benefit; SD, Stable Disease; ET, endocrine therapy; CT, chemotherapy; NPLD, non-pegylated liposomal doxorubicin; Nab-P, Nab-paclitaxel; mVNR, Metronomic Vinorelbine; mCAPE, Metronomic Capecitabine; Palbo, Palbociclib; Letro, Letrozole; EVE, Everolimus; EXE, Exemestane; PLD, pegylated liposomal doxorubicin.